Chinese drug regulators approved Shenzhen Salubris Pharmaceuticals' (SHE:002294) clinical trials for its SAL0140 chronic kidney disease tablets, according to a Thursday filing with the Shenzhen bourse.
The drug is an aldosterone synthase inhibitor that maintains fluid and electrolyte balance, helping reduce end-organ damage, according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments